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Abstract 
The carryover effect is a recurring issue in the pharmaceutical field. It may strongly influence 
the final outcome of an average bioequivalence study. Testing a null hypothesis of zero 
carryover is useless: not rejecting it does not guarantee the non-existence of carryover, and 
rejecting it is not informative of the true degree of carryover and its influence on the validity 
of the final outcome of the bioequivalence study. We propose a more consistent approach: 
even if some carryover is present, is it enough to seriously distort the study conclusions or is it 
negligible? This is the central aim of this paper, which focuses on average bioequivalence 
studies based on 2×2 crossover designs and on the main problem associated with carryover: 
type I error inflation. We propose an equivalence testing approach to these questions and 
suggest reasonable negligibility or relevance limits for carryover. Finally, we illustrate this 
approach on some real datasets. 
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1. INTRODUCTION 
Average bioequivalence (ABE) studies are performed to demonstrate that the ratio of 
geometric mean bioavailabilities (BA) of a brand or reference (R) drug and a generic or test 
drug (T) lies within pre-specified limits of equivalence. In the original scale of measurements, 
these limits are typically 0.80 and 1.25 [1]. Bioavailability is measured in terms of specific 
variables like “area under the curve until time t”, AUC0-t, or maximum concentration, Cmax.  
 
Normally, a logarithmic transformation of data is recommended. In the transformed scale, 
these limits become ±0.2231 and the difference of mean log-bioavailabilities, the formulation 
effect, must lie between them. Most regulatory agencies recommend that ABE studies be 
based on a 2×2, RT/TR, crossover design (two treatments, two periods and two sequences) 
and inference on the TOST (two one-sided tests) procedure. The α level TOST is 
operationally equivalent to the interval inclusion principle, say, to declare ABE if the usual 
parametric normal 1 – 2α “shortest” confidence interval for the formulation effect lies within 
the bioequivalence limits. 
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Crossover designs allow within-subject comparison, but, as each subject receives a sequence 
of treatments, a carryover (or residual) effect may occur in the second (and any subsequent) 
administration period of the assay [1]. One of the assumptions underlying the standard ABE 
methods based on crossover trials is that carryover effects are absent [1]. In theory, we can 
avoid, minimise or rule out these effects if there is a presumed sufficient washout time 
between drug administrations. It is recommended that washout periods exceed five drug 
elimination half-lives [1], [2]. 
 
Given the possibility of disturbing carryover effects, Grizzle [3] proposed a two-stage 
procedure for the analysis of data from 2×2 crossover studies. First, to test the null hypothesis 
of non-existence of carryover at a significance level of α = 0.1, or even 0.15, to ensure there is 
enough power. In case of non-rejection of the null hypothesis, he recommended proceeding 
with the standard analysis under no carryover. Otherwise, the recommendation was to use 
only the data from the first period, like data obtained in a fully randomised parallel trial. This 
strategy has been recommended in the past by the FDA [1], and is widely used in practice 
despite much criticism ([4], [5], [6], [7], [8]). The two-stage procedure is not mentioned in 
recent regulations (e.g. [2]). 
 
Opponents of the two-stage procedure state that the best policy is not to test for carryover 
beforehand (or not to use this test as a basis for any further decisions on the analysis course) 
and to proceed as if it were absent. In well-performed experiments, carryover will commonly 
be absent, as the washout will normally succeed in eliminating it. This opinion seems to be 
confirmed by D’Angelo et al. [9] in their review of 324 two-way and 96 three-way crossover 
studies. Only a small proportion of these studies, compatible with the common significance 
level at which they were performed, resulted in a significant carryover. Moreover, for the 
subset of studies reporting the p-value, its empirical distribution was very close to the 
uniform. With these data, this distributional null hypothesis is never rejected by the 
Kolmogorov-Smirnov (KS) test [8]. These results are contested in [10] and [11], with 
simulations that suggest the lack of power of these KS tests. Senn et al. in [12] rebut these 
arguments, arguing the irrelevance of power calculations to interpret observational data. 
However, a presumed proper washout time doesn’t always guarantee that carryover effects are 
removed, as is suggested, for example, in [13] and [14] (contested by [15]). Mills et al. in [16] 
review the methodological aspects of 116 crossover studies and conclude that carryover may 
likely be present in some of them. Their arguments mainly concern the design, including the 
lack of washout, and not the outcome of a carryover significance test. In a 71% of papers, the 
possibility of carryover is not taken into consideration in the methods section. Similar 
conclusions are reported in [17]. 
 
In recent years, a growing body of pharmacogenetics evidence also suggests that avoiding 
carryover in bioequivalence studies may pose problems. Peiró et al. in [18] identify a SNP 
polymorphism associated with cytochrome P-450 (CYP2C9*3), directly related to the 
pharmacokinetics of Tenoxicam. It may affect a bioequivalence study if, by chance, different 
proportions of each genotype are assigned to each sequence, as it is related to low drug 
clearance and high AUC0-∞ and t1/2 (high-life time) values. The study was developed in 18 
healthy volunteers. A detectable plasma drug concentration before the second administration 
(and after a presumed adequate washout period of 21 days) was observed in five volunteers. 
This situation could strongly influence the existence of carryover. Bioequivalence is declared 
when all volunteers are considered, but no bioequivalence is declared if only the volunteers 
with a particular variant of the polymorphism (CYP2C9) are considered. Wu et al. in [19] 
describe three different types of pharmacokinetic behaviour related to individual genotypes, 
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the so-called extensive, high and early metabolisers. The above results seem to reinforce the 
experimental grounds of the simulation studies in [20], where differences in pharmacokinetic 
behaviour between individuals may induce some carryover. It seems unquestionable that the 
genetic characteristics associated with the metabolising ability (high, medium or slow) of the 
volunteers in a bioequivalence study directly affect the concentration of a drug in the second 
period, and that, despite a presumed adequate washout period, in some cases a percentage of 
the drug is left over from the first period. 
 
Carryover considerations aside, in more general statistical terms any pre-testing strategy like 
Grizzle’s two-stage procedure should be avoided, as it leads to invalid tests which do not 
respect the nominal global test size [6, 21]. On the other hand, if used as a complementary 
diagnostic instead of a pre-test, it provides some insight on possible carryover, which seems 
desirable in any crossover study. But testing a null hypothesis of zero carryover is useless: not 
rejecting it does not guarantee the non-existence of carryover, and rejecting it is not 
informative of the true degree of carryover and its influence on the validity of the main 
conclusions of the study, e.g. to conclude bioequivalence (or not). In other words, statistical 
significance is not synonymous of relevance.  
 
A more reliable approach would be equivalence testing: even if some carryover is present, is 
it enough to seriously distort the study conclusions or is it negligible? This is the point of 
view taken in this paper, with average bioequivalence studies based on 2×2 crossover designs 
as the main goal. 
 
In the next section, we summarise some results and notation. In section 3, an approach for 
establishing the equivalence or negligibility limits (and their complementary relevance limits) 
for carryover in ABE studies is proposed. Section 4 introduces an equivalence testing 
procedure based on these limits. Section 5 is devoted to some illustrative examples. The paper 
concludes with a short discussion and some conclusions. 
 
2. BASIC RESULTS AND NOTATION 
 
In a 2×2 crossover design, each experimental subject receives a single dose of both 
formulations, R and T, in only one of two possible orders or treatment sequences, RT or TR. A 
sample of N = n1 + n2 subjects are randomly allocated, n1 to sequence RT and n2 to sequence 
TR. For a given variable Y in the logarithmic scale, say, Y = log Cmax or Y = log AUC0-t, Yijk 
will designate an observation made on the i−th individual, in the j−th period and the k−th 
sequence, i = 1, …, nk, j = 1,2 and k = 1,2.  
We consider the following underlying linear model: 
( , ) ( 1, ) ( )µ −= + + + + +ijk j j k j k i k ijkY P F C S e    (1) 
where µ is a global mean, Pj is the fixed effect of the administration period j, F(j,k) is the fixed 
effect of the formulation administered on the k-th sequence and j-th period, and C(j-1,k) 
corresponds to the fixed effect of carryover. The possible carryover effect of the reference 
formulation from the first period to the second period in sequence 1 is denoted by CR, while 
the equivalent effect of the test formulation in sequence 2 is denoted by CT. Therefore: 
4 
 
 ( 1, )
if 2 and 1
if 2 and 2
0 otherwise
−
= =

= = =


R
j k T
C j k
C C j k  
with CR = − CT = C. Similarly, 
 ( , )
      if     
      if     
=
= 
≠
R
j k
T
F j k
F
F j k  
with FR = − FT = F, and P1 = −P2 = P as we consider 
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1
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=∑ jj P   
We will designate the formulation effect as φ = FT – FR = –2F, the carryover effect as κ = CT 
– CR = –2C and the period effect as pi = P2 – P1. ( )2( ) 0,σ∼i k SS N  represents the random effect 
of the i-th subject nested in the k-th sequence. 2σ S  is the inter-subject variance. 2(0, )σ∼ijke N  
is the random error, residual or disturbance term. Additionally, we assume independence 
between all Si(k), all eijk, and mutual independence between the {Si(k)} and the {eijk}. 
For simplicity we assume constant residual (or within or intrasubject) variance, 2.σ  
The inference on the formulation effect is based on the period difference contrasts for each 
subject i within each sequence k, 2 10.5 ( )= −ik i k i kd Y Y . Its expectation and variance are: 
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2
1 if 2
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1
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      (2) 
If 
1
1
=
= ∑
kn
k ik
ik
d d
n
 are the sample means of the period differences, its difference: 
 1 2= −D d d          (3) 
is an unbiased estimate of the formulation effect φ, provided that no carryover is present, i.e. 
if κ = 0. But in general, D is a biased estimator of φ: 
 ( ) 1 .2φ κ= −E D         (4) 
The variance of the semidiference contrasts dik may be estimated as: 
 ( )2 22 2
1 1
1 1
ˆ ˆ
2 2
σ σ
= =
= − =
−
∑∑
kn
d ik k
k i
d d
N
      (5) 
and then the standard error of D  can be independently estimated by 
 

1 2 1 2 1 2
1 1
ˆ ˆ ˆse .
2
σ σ σ= + = =D d d
N N
n n n n n n
     (6) 
According to the confidence interval inclusion principle, ABE is declared if the 1 – 2α 
“shortest” confidence interval: 
 
1
2 se
α−
−
± DND t          (7) 
lies within the bioequivalence limits. In (7), 1 2α−−Nt  corresponds to the 1 – α quantile of a 
Student’s t distribution with N – 2 degrees of freedom. 
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While inference on the formulation effect is typically based on the difference contrasts, the 
inference on the carryover may be based on the sums of observations within each subject 
along all periods. Using the common “dot” notation, writing 1 2= +ii k i k i kY Y Y  we have: 
 ( ) 2 if 1 (in sequence 1)
2 if 2 (in sequence 2)
µ
µ
+ =
= 
+ =
i
R
i k
T
C k
E Y
C k
    (8) 
and 
 ( )2 2 2var 4 2σ σ σ+ = = +ii k SY        (9) 
that may be estimated as: 
  
( ) ( )1 22 21 1 2 2
2 1 1
ˆ .
2
σ = =+
− + −
=
−
∑ ∑i ii i ii
n n
i i
i i
Y Y Y Y
N
     (10) 
From the above results, the usual estimator of the carryover effect may be expressed as: 
 
2 1
2 1 2 1
1 12 1
1 1
κˆ
= =
= − = −∑ ∑ii ii i i
n n
i i
i i
Y Y Y Y
n n
      (11) 
with variance: 
 ( ) 2
1 2
1 1
ˆvar .κ σ +
 
= + 
 n n
       (12) 
For a more in-depth introduction to these matters see, for example, [22] or [23]. 
 
3. ESTABLISHING CARRYOVER NEGLIGIBILITY (OR 
RELEVANCE) LIMITS 
 
The numerical specification of the equivalence limits depends on each field of application, 
e.g. as a consensus among experts in the field. This is the origin of the 0.80/1.25 or ±0.2231 
limits used in ABE [1]. Many studies on the impact of carryover in crossover assays refer to 
the case where the end goal of these assays is establishing difference and the main magnitude 
under consideration is the test power. For example, in this context, Willan and Patter [24] 
obtained a threshold for the relative carryover, κ /φ, in order to determine which strategy 
(either analysing the full set of data or only data from the first period) is better in terms of 
power. 
 
In a previous paper [25] Sanchez et al. established that the most disturbing effect of carryover 
in bioequivalence studies is the considerable increase in the probability of type I error or 
consumer risk, that is, of inappropriately declaring bioequivalence. This inflation occurs when 
the carryover effect and the formulation effect both have the same sign (and then the relative 
carryover κ /φ is positive), in accordance with the fact that the expectation of the usual 
estimator of the formulation effect is φ – κ / 2. Then, in a scenario of true non-bioequivalence 
(e.g. positive φ, to the right of the bioequivalence limit), if the true carryover effect has the 
same sign as the formulation effect (e.g. it is positive), the estimated values of the formulation 
effect will more frequently tend to be within the bioequivalence limits (e.g. left-deviated with 
respect to φ). On the other hand, when the carryover effect and the formulation effect have 
different signs, the size of the usual bioequivalence test is only slightly reduced. Thus, it 
seems appropriate to establish carryover negligibility limits in terms of its tolerable impact on 
the true test size, say α*. With a fixed nominal ABE significance level α (e.g. the usual 0.05), 
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our proposed strategy will be to determine the maximum tolerable value of α* over α (e.g. 
two times α) and then to determine the level of carryover in which this level of true type I 
error is reached. 
 
In Appendix I, we conclude that the crucial parameter in establishing carryover negligibility 
should be based on the scaled carryover, κ /σ. Specifically, we recommend the parameter θ 
defined as: 
 
( ) ( )1 2/ / 2n n Nθ κ σ=
                                                                       (13) 
A good, simple approximation to the negligibility limit in terms of this parameter is:  
 ( )1 *0 1 αθ α− −= Φ + z         (14) 
where Φ corresponds to the N(0,1) distribution function and z1−α to its 1 – α quantile. On the 
other hand, this negligibility limit may be computed more exactly (resulting in slightly more 
permissive negligibility limits), without a great deal of computational effort. In any case, 
irrespective of the origin of the limits, the carryover negligibility problem should be stated as 
an equivalence problem: 
 
1 2 1 2 1 2
0 0 0 1 0 0: or vs : .2 2 2
κ κ κθ θ θ θ
σ σ σ
≤ − ≥ − < <
n n n n n nH H
N N N
 (15) 
 
Alternatively, a carryover relevance test, to prove the existence of a very disturbing level of 
carryover (out of a given threshold θ0 associated with a given unacceptable level of consumer 
risk, α*) should be stated as the complementary problem: 
 
1 2 1 2 1 2
0 0 0 1 0 0: vs : or .2 2 2
κ κ κθ θ θ θ
σ σ σ
− ≤ ≤ < − >
n n n n n nH H
N N N
 (16) 
Note that greater sample sizes and/or lesser residual variabilities will tend to make 
( ) ( )1 2/ / 2θ κ σ= n n N  greater. In other words (and perhaps counter-intuitively at first 
sight), the same level of carryover will affect type I error to a greater extent than with smaller 
sample sizes and/or greater variability. This tendency and the validity of the above limits was 
confirmed in the simulations in [25] and in the simulations presented below. Note also that 
Wellek’s test of carryover negligibility ([26], p. 284) is not directly applicable to (15), as its 
scaling variance is 2 2 24 2σ σ σ+ = +S  while the scaling considered here is based on the residual 
variance σ2. 
 
Figure 1 
 
 
4. TESTING CARRYOVER NEGLIGIBILITY AND RELEVANCE 
4. 1. Carryover negligibility 
The testing problem (15) for carryover negligibility may be rewritten as: 
 
2 2
2 21 2 1 2
0 0 1 0: vs :2 2
κ κθ θ
σ σ
   ≥ <   
   
n n n nH H
N N
 
or, equivalently: 
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2 2 2 2 2 2
0 0 1 0
1 2 1 2
2 2
: 0 vs : 0.κ θ σ κ θ σ   − ≥ − <   
   
N NH H
n n n n
   (17) 
Note in advance that there may be some confusion because we are concerned with three 
“alpha” values: the nominal significance level α of the BE test, the limit of permissibility for 
its true BE test size, α*, and the significance level at which we are testing if carryover is 
negligible, test (17). From now, this last significance level will be designated as α ′ . 
Let ηU  be the upper limit of a 1 α ′− confidence interval ( , η −∞ U  for 2 2 20
1 2
2
.η κ θ σ = −  
 
N
n n
 
According to the interval inclusion principle, to reject H0 if 0η <U  defines a test of sizeα ′ . 
This upper limit may be derived using the Howe’s method, [27], adapted to a bioequivalence 
context in [28] and [29]. For a linear combination of parameters θ∑ j jc , like η  with 
( )( )2 21 1 2 1 2 01, , 2θ κ θ= = = −c c N n n 22and ,θ σ=  let Ej be independent point estimators  for 
each summand cjθj and Uj be the corresponding upper limits of 1 α ′− one-sided confidence 
intervals for cjθj. If ( )2= −j j jD U E then: 
,η = +∑ ∑j jU E D       (18) 
is the upper limit of an approximate 1 α ′− one-sided confidence interval for η.  
Unfortunately, the variance of the usual estimator of κ is 2 ,σ +  which depends on the intra and 
inter subject variation and is usually large. The variance of ˆ ˆκ σ  is even larger due to the 
random denominator. As a consequence, the test for (17) based on (18) tends to be biased for 
the most reasonable α* values, like 0.06 (a 20% increase over 0.05), 0.1 or 0.15 for a nominal 
α = 0.05, even using “permissive” values 0.10 or 0.15α ′ =  in the same line suggested by 
Grizzle in [3]. Their power properties improve for more extreme values like α *= 0.50, but the 
statement that carryover “is negligible” because “the risk of inadequately declaring ABE is 
not over 0.50” lacks any interest. 
So, for the moment, the problem of carryover negligibility must remain in a descriptive but 
not inferential status: the estimate of the scaled carryover (13) may only suggest lack of 
alarming carryover levels.On the other hand, limited but possibly more interesting results may 
be obtained for the reciprocal problem of carryover relevance. 
4.2. Carryover relevance 
A test of carryover relevance for the problem (16) may be of interest for “large” values α* like 
0.10 or 0.20, as an a posteriori diagnostic of extreme carryover. An interesting value is α *= 
0.50; then, rejecting the null hypothesis of carryover negligibility will suggest that the BE 
study under consideration has a user’s risk control not better than simply tossing a coin and 
deciding to declare BE or not, ignoring data. If τ = 1 / θ, that is, ( ) ( )1 2/ 2 / ,τ σ κ= N n n the 
above problem reduces to an equivalence or negligibility problem:
 
 
2 2
2 2 2 21 2 1 2
0 1
0 0
1 1
: 0 vs : 0.
2 2
σ κ σ κ
θ θ
      
   
− ≥ − <            
n n n nH H
N N
  (19) 
According to Howe’s method, we can obtain an upper confidence interval limit Uη for the 
parameter 
 
2
2 21 2
0
1
2
η σ κ
θ
 
= −  
 
n n
N
       (20) 
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from the estimators and upper confidence interval limits summarized in Table I: 
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Table I. Point estimators and confidence intervals to construct a confidence interval for the 
parameter η defined in (20).  
Parameter Point estimator Upper confidence interval limit 
σ2 21 σˆ=E  ( )
( )
2
1 2
, 2
ˆ 2
α
σ
χ
′ −
−
=
N
N
U  
2
21 2
0
1
2
κ
θ
  
 
−     
n n
N
 
2
21 2
2
0
1
ˆ
2
κ
θ
 
= −  
 
n nE
N
 
22
1 2
2 2
0 1 2
1 1 1
ˆ ˆmax 0,
2
ακ σ
θ
′
− +
     
= − + +     
     
N
n nU t
N n n
based on [30]) 
 
where ( )
2
, 2α
χ
′
−N
 corresponds to the α ′  quantile of a chi-square distribution with N – 2 degrees 
of freedom, and 2
α ′
−Nt  corresponds to the α ′  quantile of a Student’s t distribution with N – 2 
degrees of freedom. 
If Uη < 0 then the null hypothesis in (19) may be rejected, concluding that there is a relevant 
carryover, perhaps questioning the validity of a previous bioequivalence study declaring 
bioequivalence. This test is approximately valid provided that the intersubject variance 2σ S  is 
not much larger than the residual variance, or more precisely, provided that the intraclass 
correlation ( )2 2 2ρ σ σ σ= +I S S  is not too large. Once fixed an upper bound for the maximum 
degree of true type I error level for the relevance test, the maximum allowable ρI is a growing 
function of α*. Figure 2 displays the maximum allowable intraclass correlation for which the 
true type I error probability of the negligibility test is sufficiently closer (±20%) to a nominal 
size 0.05α ′ = , in a balanced 2×2 design for sample sizes n = 12, 24 and 36. 
 
Figure 2 
 
These results were obtained in a simulation study whose complete results and R code are 
available at  www.ub.edu/stat/recerca/materials/Carryover_negligibility_and_relevance.htm. 
Figure 3 displays a subset of the more interesting simulation results. It corresponds to the 
power curve of the relevance test (say the probability of declaring carryover relevance) when 
“relevance” is set at α *= 0.50 and the test is performed at three possible significance levels, 
0.05, 0.1 or 0.15α ′ = , for a balanced sample size n = 12. The probability of declaring 
carryover relevance is displayed in function of the parameter θ defined in (13), in terms of a 
fraction of the relevance limit θ0(α*). Each probability line corresponds to a given proportion 
between the “intra” and the “inter” subject variances, 2σ  and 2Sσ , expressed in terms of a 
given value of intraclass correlation, ρI. Ideally, the probability of declaring carryover 
relevance should be below α ′ (horizontal thick line) for fractions at left of 1 in the abscises 
axis, it should be exactly 0.05 for a unit fraction and should be above this reference value for 
fractions at right of 1. This behavior is acceptably displayed in all situations except when the 
intraclass correlation is too high. 
 
Figure 3 
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5. NUMERICAL EXAMPLES 
5.1 Example 1 
 
We illustrate the above procedures using a dataset, which is accessible through the FDA 
website. It corresponds to dataset 29, “Cholinesterase inhibitor”, in Section II, which is 
devoted to non-replicate designs, at: 
 http://www.fda.gov/downloads/Drugs/ScienceResearch/UCM301914.txt. 
These data correspond to a balanced 2×2 crossover design for a total of N = 28 subjects, n = 
14 in each sequence. The measured variables were the area under the curve until time t, 
AUC0-t, and the peak plasma concentration of a drug after oral administration, Cmax. 
Table II shows the main results of a standard bioequivalence and ANOVA analysis. ANOVA 
is performed through a parameterisation that allows for estimation of the overall mean, period 
effects, treatment effects and carryover effects, assuming that no sequence effects exist. The 
drug has low within-subject variability and the study has adequate power, provided that the 
number of healthy volunteers included in the protocol is sufficient. For both variables, the 
standard ANOVA or Student’s t test procedures reject the null hypothesis of null carryover 
effect, κ = 0, but do not give any idea of the magnitude of these non-null carryovers and their 
possible impact on a bioequivalence study. 
 
Table II. ABE and ANOVA analysis 
 
Bioavailability 
measure 
90% IC 
shortest* 
(regulatory) 
TOST* 
(p-value superior 
and inferior) 
 
carryover effect p-value 
(ANOVA)** 
AUC0-t [96.60; 106.79] Bioequivalent 
<0.0001 
<0.0001  
0.0236 
 
     
Cmax [96.87; 111.00] Bioequivalent 
<0.0001 
<0.0001  0.0318 
* Procedure TTEST and TOST calculated with SAS v. 9.2 ** Calculated with STATA v. 11.00, by parameterisation #1 
 
Bioavailability 
measure 
Within-subject coefficient of 
variation [%] 
Minimum required sample size, 
n for sequence, N total* 
Calculated power of 
the BE test 
AUC0-t 10.03 n1= n2=8, N=16 91.41% 
Cmax 14.21 n1= n2=12, N=24 86.82% 
* Calculated with R library PowerTOST 
 
For the logarithmically transformed AUC0-t,, the estimated carryover (expression (11)) is 
ˆ 0.7568κ =−  and the residual standard deviation ˆ 0.1166.σ =  This makes ˆ ˆ 6.4878κ σ = −  and 
the estimated θ parameter becomes 12.1376.−  Considering a limit for type I error * 0.50,α =  
and the standard α = 0.05 for the bioequivalence test, the associated relevance limits for 
standardised carryover become 0 1.6889θ± = ± , so the estimated θ is more than seven times 
this limit. This may be interpreted as a suggestion of a possibly highly relevant carryover. In 
fact, the test for carryover relevance proposed in section 4 gives a significant result at a 
standard significance level 0.05α ′ = as the upper limit of the one-sided confidence interval 
for the parameter (20) is negative: −0.0457. Following Grizzle’s recommendation of testing 
carryover with more permissive significance levels, like 0.10 or 0.15, the preceding result is 
still clearer, for example for 0.15α ′ =  the confidence interval upper limit becomes −0.2969. 
These results must be taken with care as the estimated intraclass correlation is very high, 
0.9245, which makes the relevance test too permissive, according to Figures 2 and 3. They 
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may suggest the convenience of revising the experimental protocols, but should not be taken 
as a full evidence of distorting carryover. 
For the logarithmically transformed Cmax, the corresponding values are ˆ 0.4782κ = −  and 
ˆ 0.1453.σ =  Then ( ) ( )1 2ˆ ˆ ˆ/ / 2 6.1585θ κ σ= = −n n N  suggests a carryover level of nearly 
four times the relevance limit 0 1.6889.θ± = ±  Again, relevant carryover may be suspected. 
This is not corroborated at 0.05α ′ =  (upper limit of the confidence interval 0.0042) but for 
0.15α ′ =  the confidence interval limit is negative, −0.0588, which conducts to the rejection 
of the null hypothesis of irrelevant carryover. This result is more reliable as the estimated 
intraclass correlation, 0.7608, lies within the validity range of the test. 
It is worth to say that for both bioavailability variables, the formulation effect estimates D  
were positive (and so with a different sign than the carryover estimate), although very close to 
zero: 0.0051 and 0.0363 respectively for AUC and Cmax. Only when the formulation effect 
and the carryover effect have the same sign, carryover is potentially dangerous with respect to 
type I error distortion. On the other hand, the evidences of strong carryover, under expression 
(4) suggest that the formulation effect estimate may be strongly biased towards positive 
values.  The negative values of alternative formulation effect estimators like the one based 
only on the first period data, say 1 12 11ˆ Y Yφ = −i i  (= −0.3733 and −0.2028, for AUC and Cmax 
respectively) where 11 1 11
jn
k i ki
Y n Y−
=
= ∑i stands for the mean of all observations in period 1 and 
sequence k, and the synthetic estimator of Longford [31] (−0.2161 and −0.0787, respectively) 
which is based on a weighted average of D  and 1ˆφ , give some credibility to the possibility of 
a truly negative formulation effect and thus to the formulation effect and the carryover effect 
having the same sign. 
 
 
Table III. Carryover relevance analysis 
 
Parameter Estimated 
carryover Estimated θ  Carryover limits ±θ0  
Upper limit Uη. Negative 
value ⇒ carryover 
relevance at 
α′=0.05 (α′=0.15) 
AUC0-t −0.7568 −12.1376 
±1.6889 
(θ is 7.2 times θ0) 
 
−0.0457 (−0.2969) 
    
 
Cmax −0.4782 −6.1585 ±1.6889 (θ is 3.6 times θ0) 
  0.0042 (−0.0588) 
 
5.2 Example 2 
 
As a second example, we use the results of a true but unrecognisable bioequivalence study 
available at www.ub.edu/stat/recerca/materials/Example2Carryover.pdf.   
In short, for a balanced sample size of 12 in each sequence, for all three pharmacokinetic 
parameters, the ANOVA for carryover is non-significant at a 0.05 level. The p-values are 
0.1859, 0.2077 and 0.1123 for the logarithms of AUC0-t, AUC0-∞ and Cmax, respectively. The 
null hypothesis of zero carryover may be rejected for Cmax using the more permissive level 
0.15. But in any case these results do not provide any indication on the true distorting effect 
of carryover on the BE study, if present. For example, one may question if these carryovers 
may put the probability of erroneously declaring BE at an unacceptable α* = 0.50 level. 
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For Cmax, the estimated carryover is 1.096 and the estimated within-subject σ is 0.333 which 
gives an estimated θ value of 5.699. Testing relevance at a 0.05 level, 5.699 corresponds to 
more than 3 times the relevance limit θ0 = 1.6977. These results seem to suggest carryover 
relevance, but the upper confidence interval limit Uη is 0.114 so no significant carryover 
relevance may be declared. On the other hand, if relevance is also tested at a 0.15 level, the 
upper confidence interval limit Uη becomes −0.0485 and carryover relevance is declared, thus 
suggesting evidence for an unacceptable user’s risk of 0.50 of incorrectly declaring 
bioequivalence. The intraclass correlation for Cmax is 0.8446, in the limit but still supporting 
a credible carryover relevance test. 
The same results (evidence of relevant carryover at a 0.15 level but not at 0.05, when the 
possibility of reaching a true type I error probability 0.5 is considered) are obtained for the 
other two pharmacokinetic parameters, but at very high intraclass correlation values, 0.9538 
and 0.9566 for AUC0-t and AUC0-∞ respectively, which decrease the credibility of the 
corresponding relevance results. 
 
6 DISCUSSION 
 
In our opinion, there is enough evidence to state that some factors may directly affect the 
concentration of a drug in the second period of a crossover study, and that, despite a presumed 
adequate washout period, sometimes a certain degree of carryover may be present. Among 
these factors, there is the possible presence of phenotypes associated with metabolising ability 
(e.g. extensive, intermediate, poor and ultra-rapid metabolizer, [32]) in the volunteers who 
participate in a bioequivalence study, a factor that may directly affect the concentration of a 
drug in the second period. Provided that the frequencies of the alleles associated to these 
phenotypes may vary across human groups, these considerations also pose some doubt in the 
automatic transportability of bioequivalence studies between countries or ethnical groups. 
Obviously, these considerations are only relevant (for carryover) if the differences in 
metabolizing ability are translated in some way to differences associated with the different 
formulations. 
Our first example was chosen quite deliberately to illustrate a case where high carryover was 
suspected in advance due to heterogeneity with respect to gender. These effects of subgroup 
heterogeneity (gender, phenotypes, age, etc.) that induce some subject-by-formulation 
interaction (confounded with the carryover effect) have been emphasized by the regulators. 
Chapter III of [33], “Methods to document BA and BE, Part A, Pharmacokinetic Studies, item 
5. Study Population” recommends that “in vivo BE studies be conducted in individuals 
representative of the general population, taking into account age, sex, and race. We 
recommend that if the drug product is intended for use in both sexes, the sponsor attempt to 
include similar proportions of males and females in the study”. Here we are dealing with 
subject-by-formulation interaction and not with representativeness, but it is worth pointing 
that there is also some scepticism among specialists concerning these recommendations, as 
BE studies are performed on healthy volunteers and not in patients, and presumably 
representativeness will be not an issue. 
Therefore, ignoring the carryover issue in bioequivalence studies may not be the best strategy, 
especially given that carryover may severely affect the type I error, that is to say, the user risk 
associated with wrongly declaring bioequivalence. We suggest that bioequivalence studies 
should be accompanied by some analysis exploring the possible presence of disturbing 
degrees of carryover, as a way of reinforcing its credibility or lack thereof. In its present 
status, a positive result of the testing procedure for carryover relevance may not be presented 
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as a feasible proof of inadequacy of the BE study (and even more clearly, the test for 
carryover negligibility may not be presented as a proof of its adequacy), but perhaps should 
be taken by a regulatory authority as a suggestion for the convenience of requiring more 
information about the experiment to the applicant laboratory. 
The above comment suggests where our method may be of main interest: when analysing data 
coming from an external source, with limited control on the amount of information available 
by the analyser (e.g. a journal reviewer or a regulatory agency examining a generic 
application). There are other possible ways of evaluating carryover, e.g. using baseline 
measurements before the second administration; our method may conduct to conclude that 
such complementary information is necessary and to seek for it. 
In any case we are not promoting a two-stage approach to BE determination. Our point of 
view is strictly one-stage, always assuming null or negligible carryover and thus the 
correctness of the decision on BE based on the confidence interval (7). But in the same way 
that, for example, a look to the residuals is always advisable, a look to any suspected trace of 
possible disturbing carryover may be a good policy, possibly for asking for supplementary 
information on the experiment, with the desirable end goal of finally stablishing its 
correctness.    
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Appendix I. Determining the carryover negligibility limits 
 
Consider an ABE assay where the usual test (i.e. TOST/Interval inclusion principle for the 
“shortest” confidence interval) is unbiased. In other words, with a fixed significance level α, 
the probability of rejecting the null hypothesis of bioinequivalence will be ≤ α if this 
hypothesis is true and ≥ α otherwise. This will exclude some possible cases from our 
consideration, such as the study of a high variability drug under insufficient sample size. Let 
the null hypothesis of bioinequivalence be true. Then, the true unknown formulation effect 
will verify φ ≥ φ0 (= 0.2231, usually) or φ ≤ −φ0. We will wrongly reject H0 and declare ABE 
17 
 
if the confidence interval (7) is fully included in the interval [−φ0, +φ0]. The probability of this 
event, i.e. the probability of type I error, is: 
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The above quantity may be approximated by simulation, generating a large number m (e.g. 
106) of independent 
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A simple approximation to (21) may be derived by substituting the estimate of the residual 
standard deviation by the corresponding population value σ : 
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Then, this probability depends on the fact that: 
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Standardising the above variable, we have: 
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where Φ corresponds to the N(0,1) distribution function. The worst case, the maximum type I 
error probability corresponding to the bioequivalence test size, is reached in the 
bioequivalence limit, when φ0  = |φ |: 
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Note that the crucial parameter is the scaled carryover: ( ) ( )1 2/ / 2θ κ σ= n n N . The 
expression above provides values of the true test size that approximate the exact (21) values. 
Provided that when κ = 0, α∗ should equate α, this approximation may be improved by 
substituting the critical t value by the normal quantile, z1−α: 
 
* 01 2 1 2 1 2
1 1
22 .
2 2α α
φκ κ
α
σ σ σ− −
   
≅ Φ − − Φ + −      
   
n n n n n n
z z
N N N
  (24) 
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Numerically inverting function (24) –or inverting a table of pairs (θ, α*) coming from the 
exact expression (22)– the equivalence (negligibility) limits ±θ0 for the standardised carryover 
( ) ( )1 2/ / 2θ κ σ= n n N may be determined. In fact, α* also depends on σ, unknown, in the 
denominator of φ0 / σ. But even for small sample sizes like n1 = n2 = 6, 
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and then 
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n n
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that may be inverted in exact form: 
 ( )1 *0 1 .αθ α− −= Φ +ɶ z         (26) 
Once α* and α are fixed, 0θɶ  in (26) corresponds to the limit when max{n1,n2} →∞ of θ0 
obtained from the exact probabilities (22). Provided that 0 0θ θ<ɶ  (though they are always very 
similar quantities), 0θɶ  may be considered a simple, pessimistic approximation to the true 
negligibility limit θ 0, although this is not difficult to precisely approximate by simulation. For 
example, if α = 0.05 and α∗ = 0.1, for a sample size of n1 = n2 = 12, then the negligibility limit 
of the scaled carryover is θ 0 = 0.3742 and 0 0.3633θ =ɶ . 
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Figure 1. Negligibility limit for scaled carryover, ( ) 1 2/ / (2 )θ κ σ= n n N , in function of 
the maximum allowable type I error, α*, for diverse sample sizes (n = n1 = n2 corresponds to 
each sequence size in a balanced design, n = Inf corresponds to the approximation (13)). 
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Figure 2. Maximum allowable intraclass correlation to ensure approximate validity of 
the test for carryover relevance. Too high intraclass correlations may seriously distort the 
test for carryover relevance. In order to assure a true type I error probability of the relevance 
test sufficiently closer (±20%) to a nominal size 0.05α ′ = , in a balanced 2×2 design for 
sample sizes n = 12, 24 and 36, the intraclass correlation should not be greater than these 
values. 
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Figure 3. Probability of declaring relevant carryover.  When “relevance” is set at α *= 0.50 
and the test is performed at three possible significance levels, 0.05, 0.1 or 0.15α ′ = , for a 
balanced sample size n = 12 in a 2×2 crossover design. The probability is displayed in 
function of the carryover relevance parameter θ defined in (13), in terms of a fraction of the 
relevance limit θ0(α*),θ /θ0. Fraction values below 1 reflect non-relevant carryover degrees, 
fraction values above 1 reflect relevant carryovers, able to put the true user risk at a too high 
α *= 0.50 in a BE study. Each probability line corresponds to a given proportion between the 
“intra” and the “inter” subject variances, 2σ  and 2Sσ , expressed in terms of a given value of 
intraclass correlation, ρI. 
  
 
 
 
